<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Addict Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Addict Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Current Addiction Reports</journal-title></journal-title-group><issn pub-type="epub">2196-2952</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10126560</article-id><article-id pub-id-type="pmcid-ver">PMC10126560.1</article-id><article-id pub-id-type="pmcaid">10126560</article-id><article-id pub-id-type="pmcaiid">10126560</article-id><article-id pub-id-type="pmid">37266192</article-id><article-id pub-id-type="doi">10.1007/s40429-023-00480-9</article-id><article-id pub-id-type="publisher-id">480</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Evolution of Telepsychiatry for Substance Use Disorders During COVID-19: a Narrative Review</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0006-6288-4763</contrib-id><name name-style="western"><surname>Fast</surname><given-names initials="N">Noam</given-names></name><address><email>nfast@startny.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Kessel</surname><given-names initials="R">Robin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Humphreys</surname><given-names initials="K">Keith</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ward</surname><given-names initials="NF">Natalie Frances</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roman-Urrestarazu</surname><given-names initials="A">Andres</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.432271.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0381 2872</institution-id><institution>START Treatment &amp; Recovery Centers, </institution></institution-wrap>New York City, USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.21729.3f</institution-id><institution-id institution-id-type="ISNI">0000000419368729</institution-id><institution>Addiction Psychiatry Fellowship Faculty, Department of Psychiatry, </institution><institution>Columbia University, </institution></institution-wrap>New York City, USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.13063.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 0789 5319</institution-id><institution>Department of Health Policy, London School of Economics and Political Science, </institution><institution>LSE Health, </institution></institution-wrap>London, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.5012.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0481 6099</institution-id><institution>Department of International Health, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, </institution><institution>Maastricht University, </institution></institution-wrap>Maastricht, Netherlands </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Department of Psychiatry and Behavioral Sciences, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.7177.6</institution-id><institution-id institution-id-type="ISNI">0000000084992262</institution-id><institution>Department of International Development Studies, </institution><institution>University of Amsterdam, </institution></institution-wrap>Amsterdam, Netherlands </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>Cambridge Public Health, University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>10</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">434223</issue-id><fpage>187</fpage><lpage>197</lpage><history><date date-type="accepted"><day>6</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>27</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-02 17:25:20.527"><day>02</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40429_2023_Article_480.pdf"/><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">This article aims to review and synthesize the current research evidence regarding the efficacy of telepsychiatry-delivered substance use disorder treatment using a narrative review with a focus on the effects of remote healthcare delivery within the substance abuse treatment space.</p></sec><sec><title>Recent Findings</title><p id="Par2">The COVID-19 pandemic exerted substantial pressures on all levels of society. Social isolation, loss of employment, stress, physical illness, overburdened health services, unmet medical needs, and rapidly changing pandemic restrictions had particularly severe consequences for people with mental health issues and substance use disorders. Since the start of the pandemic, addiction treatment (and medical treatment overall) using remote health platforms has significantly expanded to different platforms and delivery systems. The USA, in particular, reported transformational policy developments to enable the delivery of telehealth during the COVID-19 pandemic. However, systemic barriers such as a widespread lack of internet access and insufficient patient and provider digital skills remain.</p></sec><sec><title>Summary</title><p id="Par3">Overall, telepsychiatry is a promising approach for the treatment of substance use disorders, but more randomized controlled trials are needed in the future to assess the evidence base of available interventions.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Telepsychiatry</kwd><kwd>Telehealth</kwd><kwd>Substance use disorder</kwd><kwd>COVID</kwd><kwd>Pandemic</kwd><kwd>Review</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Substance use disorders are responsible for widespread morbidity and mortality and are drivers of the spiraling increase in healthcare spending in the USA. The Center for Disease Control reported 107,622 drug overdose deaths in the USA during 2021 and it is estimated that 40 million illnesses and injuries each year are attributable to addictive substances [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. According to the Obama Administration, the economic cost of substance misuse in the USA was estimated at $193 billion in 2007, the last available estimate, including health care costs, lost worker productivity, and crime [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. According to a 2019 survey from the Substance Abuse and Mental Health Services Administration, around 20 million teenagers and adults in the USA have a substance use disorder [<xref ref-type="bibr" rid="CR5">5</xref>], although estimates on substance use disorders from national surveys may be subject to recall bias since people with substance disorders may not disclose symptoms in a survey setting, therefore underreporting true estimates [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par5">The COVID-19 pandemic exerted severe pressures on all levels of society. Social isolation, overburdened health services, and rapidly changing pandemic restrictions led to particularly severe consequences for people with mental health issues and substance use disorders [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Social isolation, unmet needs for mental health services, and decreased access to care exacerbated the situation [<xref ref-type="bibr" rid="CR9">9</xref>]. Since the start of the COVID-19 pandemic, addiction treatment via telehealth has significantly expanded to unprecedented levels [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The increasing availability of telepsychiatry for substance use disorders, coupled with regulatory changes and increased public interest, may offer a novel opportunity to provide specialized treatment to the most vulnerable [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. While a number of previous reviews have examined the utilization and efficacy of telehealth [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], relatively few articles have examined the current state of addiction telepsychiatry using a narrative review perspective. The aim of this review is to examine advances in addiction telepsychiatry, the legal frameworks and policy developments governing its use in the USA, potential financial considerations, evidence basis for efficacy as well as potential limitations and shortcomings that should be explored in the roll out of this medium of healthcare [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec2"><title>Telepsychiatry, Substance Use, and the Pandemic</title><p id="Par6">Prior to the COVID-19 public health emergency, a vast majority (76%) of specialty addiction treatment facilities did not have the capability to engage in telemedicine encounters and there were many stigmatizing barriers to treatment for the substance-using population [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Consequently, telehealth approaches were used in approximately 0.1% of addiction treatment encounters.</p><p id="Par7">During the pandemic, substance use and mental health symptoms in vulnerable populations worsened. This consequently led to a serious worsening of pre-existing conditions and delays in treatment for those requiring acute care [<xref ref-type="bibr" rid="CR21">21</xref>]. Some commonly offered group therapy support pathways, such as Narcotics Anonymous (NA), became less accessible due to social distancing [<xref ref-type="bibr" rid="CR22">22</xref>] and started using remote meetings. The focus of healthcare systems on combating the pandemic may have decreased access to care for people with substance-related diagnoses [<xref ref-type="bibr" rid="CR23">23</xref>]. People with SUDs were less likely to attend emergency rooms due to the fear of infection [<xref ref-type="bibr" rid="CR22">22</xref>]. Social isolation of patients with substance use disorders increased the likelihood of risky drug use and heightened the risk of overdose due to a lack of oversight by peers [<xref ref-type="bibr" rid="CR20">20</xref>]. Changes in usage and supply during the pandemic meant that people who inject drugs (PWID) were at a higher risk of overdose [<xref ref-type="bibr" rid="CR19">19</xref>]. Substance-using patients are generally more prone to chronic diseases, which can then be exacerbated by continuing substance use. COVID-19 affected people with chronic conditions most severely [<xref ref-type="bibr" rid="CR24">24</xref>]. COVID-related lockdowns and consequent social isolation reduced access to basic health services for the PWID population [<xref ref-type="bibr" rid="CR25">25</xref>]. While the pandemic presented serious challenges for mental health services globally, a door opened for the transformation of health care delivery. Telemedicine advances promised an inexpensive way to engage patients meaningfully. It was also an opportunity to assess the effectiveness and feasibility of doing so. Remote medicine had been a phenomenon for a while, but it had never had the chance to be scaled up out of necessity to the level we saw during the pandemic, overcoming commonly held acceptance issues that patients and providers may have experienced before.</p></sec><sec id="Sec3"><title>Evidence on the Use of Telepsychiatry for Mental Health</title><p id="Par8">Some research has demonstrated that the use of telepsychiatry for mental health problems is possible, acceptable, and as effective as in-person therapies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. A subgroup meta-analysis of 8 articles reported a significant standardized mean difference (SMD) when comparing telehealth to care as usual (0.29 (95% CI 0.16&#8211;0.41)), indicating telehealth produced a greater decrease in depressive symptoms [<xref ref-type="bibr" rid="CR28">28</xref>&#8226;]. A rapid evidence assessment of 24 articles reported that telepsychiatry could be effective for common mental health disorders such as depression, anxiety, posttraumatic stress disorder, and adjustment disorder in a meta-analysis of synchronous treatments [<xref ref-type="bibr" rid="CR29">29</xref>&#8226;]. Virtually delivered CBT has been found to be at least equally as effective as in-person CBT for a range of mental and physical conditions [<xref ref-type="bibr" rid="CR30">30</xref>&#8226;, <xref ref-type="bibr" rid="CR31">31</xref>]. A meta-analysis of 15 articles representing 1254 participants comparing those receiving internet-delivered CBT to waitlisted individuals found a SMD of 0.62 (95% CI 0.41&#8211;0.84) [<xref ref-type="bibr" rid="CR30">30</xref>&#8226;]. Another meta-analysis of 20 studies representing 1418 participants found no meaningful difference between those receiving internet-based CBT to face-to-face treatment (SMD 0.05 (95% CI&#8201;&#8722;&#8201;0.09&#8211;0.20)). Simultaneously, a longitudinal study following 1060 patients in intensive outpatient addiction treatment in the USA found no significant differences in delivery format (<italic toggle="yes">&#967;</italic><sup>2</sup>&#8201;=&#8201;0.4, <italic toggle="yes">p</italic>&#8201;=&#8201;0.81), overall quality of life (<italic toggle="yes">F</italic>&#8201;=&#8201;2.06, <italic toggle="yes">p</italic>&#8201;=&#8201;0.13), psychological well-being (<italic toggle="yes">F</italic>&#8201;=&#8201;0.72, <italic toggle="yes">p</italic>&#8201;=&#8201;0.49), financial well-being (<italic toggle="yes">F</italic>&#8201;=&#8201;2.30, <italic toggle="yes">p</italic>&#8201;=&#8201;0.10), and the patient&#8217;s confidence to stay sober between patients receiving virtual outpatient programming treatment for SUD as opposed to in-person (<italic toggle="yes">F</italic>&#8201;=&#8201;0.21, p&#8201;=&#8201;0.81) [<xref ref-type="bibr" rid="CR32">32</xref>&#8226;]. In another narrative review, 7 out of 8 included studies comparing virtual and in-person provision of addiction treatment showed that telehealth was as effective but not better than in-person treatment in terms of retention, therapeutic alliance, and substance use [<xref ref-type="bibr" rid="CR16">16</xref>]. Further research of 100 participants in West Virginia showed no significant differences in additional substance use, average time to achieve 30/90 consecutive days of abstinence (<italic toggle="yes">p</italic>&#8201;=&#8201;0.09 and <italic toggle="yes">p</italic>&#8201;=&#8201;0.22, respectively), and treatment retention rates at 3&#160;months (<italic toggle="yes">p</italic>&#8201;=&#8201;0.99)/1&#160;year (<italic toggle="yes">p</italic>&#8201;=&#8201;0.99) between in-person and telehealth provided medication-assisted treatment for patients with OUD [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par9">A randomized non-inferiority trial of 1843 participants suggests the equivalent efficacy of virtually delivered psychotherapy compared to face-to-face treatment (<italic toggle="yes">&#967;</italic><sup>2</sup>&#8201;=&#8201;1.78, <italic toggle="yes">p</italic>&#8201;=&#8201;0.41) [<xref ref-type="bibr" rid="CR34">34</xref>&#8226;]. A randomized controlled trial of digitally delivered acceptance and commitment therapy hosting 152 participants reported reduced general (<italic toggle="yes">d</italic>&#8201;=&#8201;0.39) and social anxiety (<italic toggle="yes">d</italic>&#8201;=&#8201;0.70), but not panic symptoms (<italic toggle="yes">d</italic>&#8201;=&#8201;0.05) compared to those on the waiting list, though no differences were observed between guided and unguided interventions [<xref ref-type="bibr" rid="CR35">35</xref>]. Patients provided with a telehealth addiction consult service (ACS) during the early stages of the COVID-19 pandemic (<italic toggle="yes">n</italic>&#8201;=&#8201;473) showed lower 30-day readmission rates compared to those receiving face-to-face ACS before the pandemic (<italic toggle="yes">n</italic>&#8201;=&#8201;370) [<xref ref-type="bibr" rid="CR36">36</xref>]. Counselling via telehealth has also been described as effective for treating SUDs [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. A non-randomized cohort comparison study (<italic toggle="yes">n</italic>&#8201;=&#8201;3733 participants) supports this notion and found that those treated using telemedicine were more likely to be retained in therapy than patients treated in-person (<italic toggle="yes">n</italic>&#8201;=&#8201;1590; aOR&#8201;=&#8201;1.27 (95% CI 1.14&#8211;1.41]) [<xref ref-type="bibr" rid="CR39">39</xref>&#8226;].</p><p id="Par10">Telepsychiatry video conferencing was shown to be a successful method of supervising healthcare professionals and assessing those needing psychiatric assistance following the tsunami in Thailand in 2004 [<xref ref-type="bibr" rid="CR40">40</xref>]. A narrative review containing 134 articles reported that telepsychiatry is comparable to in-person services in terms of the reliability of clinical assessments and treatment outcomes [<xref ref-type="bibr" rid="CR41">41</xref>&#8226;]. A multi-centric clinical trial of 507 patients using an FDA-approved digital health app &#8220;reSET&#8221; also showed a significant increase in abstinence rates for patients with SUDs (OR 1.62 (95% CI 1.12&#8211;2.35)), particularly among patients with positive urine drug and/or breath alcohol screen at the point of study entry (OR 2.18 (95% CI 1.30&#8211;3.68]) [<xref ref-type="bibr" rid="CR42">42</xref>&#8226;]. The telehealth provision of methadone medication management has also been shown to improve patient retention in two separate registry-based studies in the USA and Canada [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR39">39</xref>&#8226;]. In fact, a study in Maryland showed that, out of 177 patients prescribed buprenorphine via telehealth, 57% remained in treatment after 3&#160;months, and 86% no longer used opioids illegally [<xref ref-type="bibr" rid="CR43">43</xref>]. A study of 3733 patients in Canada demonstrated that a year of telehealth-provided buprenorphine or methadone therapy was strongly correlated with reduced illegal drug use, relapse, and illegal activity [<xref ref-type="bibr" rid="CR39">39</xref>&#8226;].</p><p id="Par11">Telehealth has been shown to improve access to care, particularly for rural and underserved populations and can improve treatment for individuals in less accessible areas [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], expanding coverage but also diminishing costs. Access to telehealth depends on internet literacy and access to adequate IT connectivity and platforms. Given the lack of healthcare workers trained in addiction medicine, particularly in rural areas, telehealth provision of addiction healthcare could expand access nationwide [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], while also removing the costs of travelling to in-person appointments [<xref ref-type="bibr" rid="CR46">46</xref>]. As a result, several key barriers to seeking healthcare are ameliorated such as limited time to travel to a clinic, lack of transportation or childcare, and the stigma of being seen at a clinic [<xref ref-type="bibr" rid="CR47">47</xref>]. Telehealth provision might reduce disparities in access for people with disabilities, limited transport options, or those who live in areas with few providers able to prescribe opioid agonist treatment [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. For instance, an Addiction Telehealth Program in San Francisco was used by 67% Black and 100% unstably housed populations. These populations typically face increased barriers to healthcare provision due to a series of structural barriers such as lack of trust in the system, experiences of discrimination, and stressful living conditions that make it difficult to prioritize health [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. The high usage of this program by these patients highlights how telehealth can increase access for populations with typically decreased healthcare access and contribute to diminishing health disparities [<xref ref-type="bibr" rid="CR50">50</xref>]. Another particularly vulnerable group involves women after giving birth. Health insurance benefits end for many women at this point, leaving the postpartum period as a serious gap for accessing healthcare, and increasing the risks of relapse and overdose [<xref ref-type="bibr" rid="CR51">51</xref>]. The delivery of telehealth during this period could reduce maternal and newborn morbidity and mortality due to untreated SUDs [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par12">Specific telehealth applications have been shown to offer significant socio-economic benefits to patients and families, healthcare providers and the healthcare system. The main benefits identified were as follows: increased access to health services, the cost-effectiveness of remote interventions, enhanced educational opportunities, improved health outcomes, better quality of care, better quality of life, and enhanced social support [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR53">53</xref>&#8211;<xref ref-type="bibr" rid="CR59">59</xref>]. Telepsychiatry is more cost effective than in-person mental health services in most studies [<xref ref-type="bibr" rid="CR41">41</xref>&#8226;, <xref ref-type="bibr" rid="CR60">60</xref>]. Telehealth can increase the efficiency of patient care by optimizing the use of a health professional&#8217;s time [<xref ref-type="bibr" rid="CR61">61</xref>]. Telehealth can allow for more flexibility in work hours, the possibility of working from home, increased job satisfaction and employee retention [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. This can potentially lead to longer-lasting therapeutic relationships between patients and providers [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR64">64</xref>] There is some evidence that telepsychiatry can increase patient adherence to treatment with reduced &#8220;No-shows.&#8221; Telepsychiatry is relatively safe with few reports of morbidity, mortality, or loss of confidentiality [<xref ref-type="bibr" rid="CR41">41</xref>&#8226;]. That said, providers of telehealth for addiction noted that the relative benefit of telehealth was dependent on the service users&#8217; circumstances [<xref ref-type="bibr" rid="CR41">41</xref>&#8226;, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. New patients, homeless or isolated patients, patients with attention issues or low comfortability with technology, and patients without access to a suitable private space may not be able to leverage the benefits of digital healthcare and fare better with in-person treatment [<xref ref-type="bibr" rid="CR12">12</xref>]. Patients with time pressures, young children, and technology-literate patients may benefit more from virtual treatment [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par13">In contrast, a scoping review of 14 articles suggests that telepsychiatry may be less effective for patients with severe mental illnesses which impair cognitive ability such as schizophrenia and major neurocognitive disorder, or in patients with a significant social disadvantage, though these studies were characterized by selection bias and poor methodological quality [<xref ref-type="bibr" rid="CR67">67</xref>&#8226;]. Nevertheless, individuals with serious mental illnesses can struggle to connect cognitively and emotionally during telehealth sessions with their counsellor [<xref ref-type="bibr" rid="CR68">68</xref>]. Another systematic review of 14 RCTs of iCBT found no substantive evidence that iCBT was equally beneficial for patients with anxiety disorders as in-person services [<xref ref-type="bibr" rid="CR69">69</xref>&#8226;], starkly contrasting previously described research [<xref ref-type="bibr" rid="CR30">30</xref>&#8226;, <xref ref-type="bibr" rid="CR31">31</xref>]. It is also important to consider that more than 40% of the most rural USA counties do not have the necessary broadband infrastructure to support video based telehealth [<xref ref-type="bibr" rid="CR46">46</xref>]. There is always the hovering risk that providers may not cover telehealth adequately and patient or providers may not be fully reimbursed [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p></sec><sec id="Sec4"><title>Clinical Users of Telepsychiatry</title><p id="Par14">A 2020 systematic review containing 38 articles found that clinician satisfaction levels and attitudes towards internet-delivered mental health care were largely positive [<xref ref-type="bibr" rid="CR71">71</xref>&#8226;]. Simultaneously, the satisfaction of patients and providers with telepsychiatry has also been documented, highlighting extensive positive experiences from patients and mixed experiences from providers [<xref ref-type="bibr" rid="CR41">41</xref>&#8226;]. Some clinicians express resistance to telepsychiatry, believing it to be less effective than in-person therapy, while others express concerns about patient privacy and the impact of utilizing video technology on building rapport and a therapeutic relationship due to reduced non-verbal communications [<xref ref-type="bibr" rid="CR27">27</xref>]. Despite the positive attitudes of clinicians, they report more positive experiences with in-person sessions over sessions utilizing telehealth [<xref ref-type="bibr" rid="CR72">72</xref>], but it is not clear what patient experiences are in relation to this, or furthermore, if clinician attitudes are relevant to the clinical effectiveness of a treatment delivery system such as this. Telepsychiatry providers tended to express more concern about the negative effects of virtual methods on therapeutic rapport [<xref ref-type="bibr" rid="CR41">41</xref>&#8226;], though other factors relating to clinical hesitancy have been reported as well, such as concerns about training, confidentiality, clinician acceptance, medication management, and reimbursement [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Clinicians reported a distinct preference of video technology over telephone sessions, suggesting that the perceived utility varies across technologies [<xref ref-type="bibr" rid="CR72">72</xref>], which also resulted in an increased intention to continue using video sessions over telephone sessions. Providers have been further limited in their ability to offer medications for OUD via telehealth due to low medical insurance reimbursement, and unwillingness to implement telehealth from licensing boards, professional associations, and public oversight bodies [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Other barriers to providing telehealth medications for OUD include privacy concerns, the assumption that people with OUD would be unable or unwilling to participate, and a hesitancy from clinicians to change their current practices [<xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>]. It is interesting to note though that what is called remote medicine or telehealth in a way is using the same delivery systems that have been available for some time such as the telephone and one could even argue it has repackaged an old technology with novel terms but in essence, it is the same medium. It is an important consideration since there is a broad evidence base about clinical delivery systems using the telephone. It is not clear how one should therefore classify interventions and the degree of novelty we are experiencing.</p><p id="Par15">On the patient side, the majority of patients receiving telepsychiatric interventions reported being satisfied or very satisfied [<xref ref-type="bibr" rid="CR41">41</xref>&#8226;, <xref ref-type="bibr" rid="CR77">77</xref>], with particular value being put on the accessibility, convenience, affordability, and privacy of telepsychiatry [<xref ref-type="bibr" rid="CR77">77</xref>]. Telepsychiatry also has the ability to provide tailored support, which is often crucial for patients with SUDs [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>], while also having the potential to be more effective, cost-effective, and efficient [<xref ref-type="bibr" rid="CR80">80</xref>]. Patients were more likely to attend their telehealth appointments than their in-person appointments, and so can optimize treatment engagement [<xref ref-type="bibr" rid="CR47">47</xref>]. However, few telehealth tools are designed specifically for people who inject drugs [<xref ref-type="bibr" rid="CR81">81</xref>], and individuals with serious mental illnesses often struggle to connect cognitively and emotionally during telehealth sessions with their counsellor [<xref ref-type="bibr" rid="CR68">68</xref>], and there might be also important selection biases when assessing effectiveness because very severe patients might not be able to engage with the IT skills required and platforms used to deliver these interventions making them only fit for those experiencing milder symptoms or the more &#8220;functional-end&#8221; of the spectrum. Many people with OUD also may not have access to a quiet or private space in which to attend sessions [<xref ref-type="bibr" rid="CR47">47</xref>]. Some forms of counseling for SUD may not even be feasible via telehealth such as intensive outpatient programs [<xref ref-type="bibr" rid="CR47">47</xref>] or crisis intervention in patients with suicidal or homicidal ideations [<xref ref-type="bibr" rid="CR37">37</xref>], that often require immediate action and face-to-face assessments. Other forms that are feasible may be difficult to deliver due to low phone or internet access in the patient group [<xref ref-type="bibr" rid="CR82">82</xref>], as well as accommodation instability and financial problems [<xref ref-type="bibr" rid="CR83">83</xref>]. According to a survey of people who inject drugs in Canada, many participants had inconsistent access to phones, social media, or the internet. Only 34.5% of participants had access to a phone for a whole year&#8212;within this population, phones are often lost or damaged, and due to moving addresses and difficulties in paying phone bills [<xref ref-type="bibr" rid="CR82">82</xref>]. Overall, telemedicine providers are able to predominantly provide medication-assisted treatment to patients with OUD in urban areas, seeing as 91&#8211;99% of rural areas lacked any providers in 2015 [<xref ref-type="bibr" rid="CR84">84</xref>].</p><p id="Par16">Moving forward, four action points have been repeatedly highlighted to ensure a successful transition to telehealth for SUD treatment [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]: (1) investing in telehealth infrastructure; (2) training and equipping providers to provide treatment for SUD via telehealth; (3) providing patients with hardware, training in using telehealth services, and social and financial support; and (4) making the temporary changes to telehealth regulations permanent. As telehealth may not be suitable for all medication types for OUD patient, it is recommended that a hybrid care delivery model is developed that can manage both patient and provider needs [<xref ref-type="bibr" rid="CR47">47</xref>]. Patients in hybrid in-person/virtual programs reported higher levels of general health than those in entirely virtual intensive outpatient programming treatment for SUD [<xref ref-type="bibr" rid="CR32">32</xref>&#8226;]. Hybrid delivery systems may offer flexibility and effectiveness in many circumstances.</p></sec><sec id="Sec5"><title>Legislative Changes from the Start of Pandemic to the Present</title><p id="Par17">Before the pandemic, provision of care via telehealth for patients with SUDs was restricted by legislative and regulatory barriers including the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>], which required that prescriptions for controlled substances to be initiated <italic toggle="yes">in person</italic> and the drug Addiction Treatment Act of 2000 [<xref ref-type="bibr" rid="CR88">88</xref>], which required providers to have a waiver to be allowed to prescribe buprenorphine. State licensing requirements also prohibit many healthcare workers from treating patients using telehealth across state borders in the USA [<xref ref-type="bibr" rid="CR89">89</xref>]. Unsurprisingly, telehealth for addictions was underutilized prior to the pandemic. Studies showed low usage rates of telehealth for SUDs, that telehealth was primarily used to complement in-person care [<xref ref-type="bibr" rid="CR86">86</xref>]. Telehealth was used less for addiction treatment than for other healthcare areas [<xref ref-type="bibr" rid="CR70">70</xref>]. Telepsychiatry for mental health was used much more widely than telepsychiatry for SUDs [<xref ref-type="bibr" rid="CR86">86</xref>]. The use of telehealth services can vary according to ethnicity, age, type of organization, and service location. Clinician hesitancy to employ telehealth related to concerns about training, confidentiality, clinician acceptance, and reimbursement [<xref ref-type="bibr" rid="CR70">70</xref>]. Stakeholders called on congress to update the Ryan Haight Act to allow addiction treatment providers to register with the DEA and prescribe controlled substances through telehealth. There was a proposed legal solution related to the Opioid Crisis Response Act of 2018, which would require the Attorney General to initiate these special registrations [<xref ref-type="bibr" rid="CR90">90</xref>].</p><p id="Par18">The corona virus outbreak led to the Federal government declaration of a public health emergency. The Drug Enforcement Agency (DEA) then announced that clinicians could prescribe schedule II&#8211;V medications via telemedicine to patients, even if they had not been seen in person, so long as there were legitimate medical reasons to prescribe. This led to important changes as to the scope of what is possible in mental health service provision and this allowed the utilization of online telepsychiatry encounters, and later telephonic encounters, to start treatment for opioid use disorder with buprenorphine without seeing the patient in person. Laws were also relaxed concerning telehealth reimbursement, who can provide telehealth services, and where they can be accessed from [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. An overview of policy developments is shown in Table <xref rid="Tab1" ref-type="table">1</xref>. In tandem with these policy changes, certain calls occurred for these changes to be made permanent in order to continue the effective provision of services [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. These same calls arose surrounding the relaxation of regulations from the DEA that allow telehealth provision of services for patients with OUD, as well as to expand them nationwide [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR93">93</xref>].<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>A chronological overview of the US policy developments for telehealth during the COVID-19 pandemic</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Date</th><th align="left" colspan="1" rowspan="1">Policy change</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">27&#8211;01-2020</td><td align="left" colspan="1" rowspan="1">The U.S. Department of Health and Human Services (HHS) declared COVID-19 a nationwide health emergency. Shortly after, HHS lessened Health Insurance Portability and Accountability (HIPPA) Act requirements to allow telehealth to be provided using free platforms such as FaceTime [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">19&#8211;03-2020</td><td align="left" colspan="1" rowspan="1">The Substance Abuse and Mental Health Services Administration (SAMHSA) relaxed the requirement for in-person evaluation before prescribing buprenorphine [<xref ref-type="bibr" rid="CR96">96</xref>]. SAMHSA issues new guidance for Opioid Treatment Programs (OTPs) to prescribe buprenorphine via telehealth and liberalized the number of take-home medications, reducing in-person visits</td></tr><tr><td align="left" colspan="1" rowspan="1">31&#8211;03-2020</td><td align="left" colspan="1" rowspan="1">DEA and SAMHSA announced that prescriptions for controlled substances could be given to patients without an in-person evaluation [<xref ref-type="bibr" rid="CR97">97</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">27&#8211;07-2022</td><td align="left" colspan="1" rowspan="1"><p>The Advancing Telehealth Beyond COVID-19 Act of 2022 modifies the extension of certain Medicare telehealth flexibilities after the end of the COVID-19 public health emergency [<xref ref-type="bibr" rid="CR98">98</xref>]. Specifically, the bill provides that certain flexibilities continue to apply until December 31, 2024, if the emergency period ends before that date. These flexibilities include:</p><p>(a) beneficiaries to continue to receive telehealth services at any site, regardless of type or location (e.g., the beneficiary&#8217;s home)</p><p>(b) occupational therapists, physical therapists, speech-language pathologists, and audiologists to continue to furnish telehealth services</p><p>(c) federally qualified health centers and rural health clinics to continue to serve as the distant site (i.e., the location of the health care practitioner)</p><p>(d) evaluation and management and behavioral health services to continue to be provided via audio-only technology</p><p>(e) hospice physicians and nurse practitioners to continue to complete certain requirements relating to patient recertifications via telehealth</p><p>The bill also delays implementation of certain in-person evaluation requirements for mental health telehealth services until January 1, 2025, or the first day after the end of the emergency period, whichever is later</p></td></tr><tr><td align="left" colspan="1" rowspan="1">29&#8211;12-2022</td><td align="left" colspan="1" rowspan="1"><p>With the signing of the Consolidated Appropriations Act of 2023 [<xref ref-type="bibr" rid="CR99">99</xref>], Congress eliminated the &#8220;DATA-Waiver Program.&#8221; The Mainstreaming Addiction Treatment (MAT) Act was signed into federal law and became effective. Important changes resulting from the MAT Act include the following:</p><p>(a) elimination of the requirement for a special registration through the federal Drug Enforcement Administration (commonly referred to as an X-waiver) to prescribe or dispense buprenorphine for the treatment of opioid use disorder (OUD)</p><p>(b) elimination of the limitations on the number of patients a practitioner was permitted to treat with buprenorphine for OUD</p><p>(c) a practitioner holding a standard DEA registration to prescribe controlled substances may now prescribe buprenorphine for the treatment of OUD, without limitation to the number of patients</p><p>Additionally, the new federal law now requires all healthcare providers, with a few exceptions, who prescribe any controlled substances to complete 8&#160;h of training in the identification and treatment of substance use disorders when any practitioner first applies for a DEA registration or at the time of their next DEA registration renewal. The training requirement becomes effective in June 2023</p><p>Furthermore, the 1.7 trillion USD bill included a 2-year extension of key telehealth provisions, such as coverage for Medicare beneficiaries to have phone or video medical appointments at home. But it also signaled political reluctance to make the payment changes permanent, requiring federal regulators to study how Medicare enrollees use telehealth</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6"><title>Policy Consequences and Effectiveness of Telehealth SUD Interventions During COVID-9</title><p id="Par19">When assessing the effect of the treatment expansion for take-home methadone during the COVID-19 pandemic for stable and less stable patients, research has shown that the percentage of overdose deaths involving methadone declined between January 2019 and August 2021, though an acute increase in methadone-involved overdose deaths was observed when the policy was introduced [<xref ref-type="bibr" rid="CR100">100</xref>]. However, this acute increase was attributed to the rise in overall drug overdose deaths driven by illicitly produced fentanyl early in the COVID-19 pandemic rather than associated with the policy changes [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. Furthermore, the number of overdose deaths involving buprenorphine did not proportionally increase with the newly introduced prescribing flexibilities [<xref ref-type="bibr" rid="CR102">102</xref>]. In fact, emergency changes permitting telehealth have reportedly led to improved access to care for patients with OUD at the VICTA mental health clinic in Rhode Island [<xref ref-type="bibr" rid="CR47">47</xref>]. These findings suggest that the inflexibility of counselling systems in place before the pandemic that required in-person appointments prevented many people with OUD from receiving medical help for their condition [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par20">Studies of opioid-dependent patients on medication-assisted treatment have shown comparable outcomes for telepsychiatry and in-person intervention in 2020 [<xref ref-type="bibr" rid="CR16">16</xref>]. As previously stated, there were no differences in outcome between videoconference and face-to-face medication-assisted treatment for opioid dependents and no significant statistical difference between telepsychiatry and in-person buprenorphine medication-assisted treatment for breakthrough substance use, time to 30 and 90&#160;days of abstinence, or retention rates at 90&#160;days and 1&#160;year [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Three literature reviews (two narrative and one systematic) also reported that retention rates were higher or consistent between those receiving in-person OUD treatment and those receiving integrated treatment through telemedicine [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Telephone-based treatment shows feasibility in the treatment of OUD and was effective at initiating buprenorphine prescriptions, with minimal associated harms [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Ultimately, providing opioid agonist treatment through telehealth has been shown to be a feasible and successful option [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR39">39</xref>&#8226;]. However, there was little evidence that available opioid-related apps meet basic quality standards even though they addressed key stakeholders and were consistent with strategies to address the opioid crisis (e.g., prevention, treatment, overdose) [<xref ref-type="bibr" rid="CR105">105</xref>].</p></sec><sec id="Sec7"><title>Alcohol and Tobacco Use and Telehealth as Comparative Case Studies</title><p id="Par21">An interesting case study for telehealth is the comparison between SUD and alcohol use disorder that have used telehealth platforms for years and telehealth alcohol treatment that has been offered for years by healthcare professionals and programs specializing in addiction [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. More than 18 million Americans are currently suffering from alcohol use disorder [<xref ref-type="bibr" rid="CR5">5</xref>] making this an important element of treatment options for a large share of the American population. Outpatient psychosocial treatments for AUD, such as Alcoholics Anonymous and 12-step programs, remain popular and are utilized more than pharmacotherapy in the community [<xref ref-type="bibr" rid="CR107">107</xref>]. It is an effective tool in reducing alcohol consumption and increasing patients&#8217; accessibility to healthcare services or health providers and social support outside of healthcare settings [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. That said, Medicare and other insurers only recently expanded their coverage to encompass telehealth services [<xref ref-type="bibr" rid="CR14">14</xref>]. In the case of tobacco, the use of telehealth videoconferencing to provide small groups of patients with a smoking cessation intervention produced results similar to in-person groups [<xref ref-type="bibr" rid="CR110">110</xref>], highlighting the potential of telehealth interventions for tobacco use disorders. Other studies found higher smoking cessation rates as a result of videoconferencing than those achieved through web-based interventions or (phone-based) quitlines [<xref ref-type="bibr" rid="CR110">110</xref>&#8211;<xref ref-type="bibr" rid="CR112">112</xref>]. Simultaneously, mindfulness training via smartphone app did not lead to reduced smoking rates compared with the control groups [<xref ref-type="bibr" rid="CR113">113</xref>].</p><p id="Par22">Contingency management is behavioral therapy for substance use and related disorders and can be conducted in group settings. It uses tangible reinforcements, such as rewards and prizes, to encourage behavioral changes and ultimately abstinence (e.g., giving a patient a voucher for a negative urine toxicology) [<xref ref-type="bibr" rid="CR114">114</xref>]. Since the start of the COVID-19 pandemic, virtually delivered contingency management has been shown to be efficacious for alcohol and nicotine use disorders [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Examples of virtually delivered contingency management involve urine toxicology completed at outpatient locations with prizes electronically delivered with prepaid gift cards [<xref ref-type="bibr" rid="CR115">115</xref>]. Another behavioral therapy for substance use involves mindfulness-based interventions, which are usually a combination of mindfulness meditation linked with cognitive and behavioral approaches. These include mindfulness-based cognitive therapy, mindfulness-based relapse prevention, mindfulness-based stress reduction, and mindfulness-oriented recovery enhancement [<xref ref-type="bibr" rid="CR116">116</xref>]. These interventions have shown to reduce the misuse of alcohol, nicotine, cannabinoids, and opioids by focusing on improving the patient&#8217;s self-awareness of maladaptive feelings and thoughts, such as cravings brought on by environmental cues, while increasing adaptive control of thoughts and behaviors [<xref ref-type="bibr" rid="CR116">116</xref>]. Existing data suggest that mindfulness training may improve outcomes and that mobile applications are a feasible method of delivery for this treatment [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. All comparative case studies provide ample evidence as to the limitations and possible scope in expanding and increasing the effectiveness for telehealth interventions in SUD and include important experiences for the delivery of interventions aimed at both conditions.</p></sec><sec id="Sec8"><title>Conclusion</title><p id="Par23">This article aimed to examine advances in addiction telepsychiatry, the legal frameworks governing its use, financial considerations, evidence basis for efficacy as well as potential limitations. The COVID pandemic led to widespread societal disruption with particularly difficult effects for the poor, underserved, and chronically ill population, and among them, people with mental health and substance use disorder issues. While new research studies underscore the potential of telepsychiatry to increase access to treatments, there is still a dearth of evidence showing that telepsychiatry leads to improved retention and treatment outcomes as compared with in-person care but still requires further research and assessment of the efficacy in order to establish the evidence base for further development of these interventions.</p><p id="Par24">This review identified several avenues for future research. First, using previously established policies and platforms such as the few digital health applications for smoking cessation that have been tested in large, well-designed randomized controlled trials [<xref ref-type="bibr" rid="CR105">105</xref>], this shows a lack of a robust evidence base for the further implementation of digital health. Similarly, there are currently no FDA-approved medications for stimulant and cocaine use disorders [<xref ref-type="bibr" rid="CR115">115</xref>] which present an important burden in SUD. Second, regulatory and reimbursement frameworks fit to assess novel digital health tools need to be developed. Third, further expansion of the digital infrastructure is vital to ensure the equitable access to digital healthcare for substance and opioid abuse [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR117">117</xref>].</p><p id="Par25">Ultimately, recent legislative and administrative changes in response to the COVID-10 pandemic have opened the door for the provision and expansion of telepsychiatry for addictive disorders. Increased access to treatment can have many positive effects for patients and addiction telepsychiatry is a promising treatment approach. Current research suggests that addiction telepsychiatry is a viable tool for helping chronically ill patients receive ongoing care and preventing expensive emergency episodes. Moving forward, more studies are needed to demonstrate the potential for decreased morbidity, mortality, and healthcare spending that may be potential benefits of expanding addiction telepsychiatry.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par26">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Human and Animal Rights and Informed consent</title><p id="Par27">This study did not use human or animal subjects.</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref-list id="BSec1"><title>Papers of particular interest, published recently, have been highlighted as: &#8226; Of importance</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGinnis</surname><given-names>JM</given-names></name><name name-style="western"><surname>Foege</surname><given-names>WH</given-names></name></person-group><article-title>Mortality and morbidity attributable to use of addictive substances in the United States</article-title><source>Proc Assoc Am Physicians</source><year>1999</year><volume>111</volume><issue>2</issue><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1381.1999.09256.x</pub-id><pub-id pub-id-type="pmid">10220805</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Center for Disease Control and Prevention. U.S. overdose deaths in 2021 increased half as much as in 2020 - but are still up 15% [Internet]. 2022 [cited 2023 Feb 4]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm">https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm</ext-link></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Office of National Drug Control Policy. How illicit drug use affects business and the economy [Internet]. Washington, D.C.: White House; 2011 May [cited 2023 Feb 9]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://obamawhitehouse.archives.gov/sites/default/files/ondcp/Fact_Sheets/effects_of_drugs_on_economy_jw_5-24-11_0.pdf">https://obamawhitehouse.archives.gov/sites/default/files/ondcp/Fact_Sheets/effects_of_drugs_on_economy_jw_5-24-11_0.pdf</ext-link></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">National Drug Intelligence Center. The economic impact of illicit drug use on American society [Internet]. Washington, D.C.: Department of Justice; 2011 [cited 2023 Feb 9]. Available from: 10.1037/e618422012-001</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20&#8211;07&#8211;01&#8211;001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2020.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reuter</surname><given-names>P</given-names></name><name name-style="western"><surname>Caulkins</surname><given-names>JP</given-names></name><name name-style="western"><surname>Midgette</surname><given-names>G</given-names></name></person-group><article-title>Heroin use cannot be measured adequately with a general population survey</article-title><source>Addict</source><year>2021</year><volume>116</volume><issue>10</issue><fpage>2600</fpage><lpage>2609</lpage><pub-id pub-id-type="doi">10.1111/add.15458</pub-id><pub-id pub-id-type="pmid">33651441</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>SY</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></name><name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></name><name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></name><name name-style="western"><surname>Ganguli</surname><given-names>I</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></name></person-group><article-title>Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US</article-title><source>JAMA Intern Med</source><year>2021</year><volume>181</volume><issue>3</issue><fpage>388</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2020.5928</pub-id><pub-id pub-id-type="pmid">33196765</pub-id><pub-id pub-id-type="pmcid">PMC7670397</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Forman R, Azzopardi-Muscat N, Kirkby V, Lessof S, Nathan NL, Pastorino G, et al. Drawing light from the pandemic: rethinking strategies for health policy and beyond. Health Policy [Internet]. 2021 Dec 5 [cited 2021 Dec 29]; Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/pii/S0168851021002918">https://www.sciencedirect.com/science/article/pii/S0168851021002918</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.healthpol.2021.12.001</pub-id><pub-id pub-id-type="pmcid">PMC8645287</pub-id><pub-id pub-id-type="pmid">34961678</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Avena NM, Simkus J, Lewandowski A, Gold MS, Potenza MN. Substance use disorders and behavioral addictions during the COVID-19 pandemic and COVID-19-related restrictions. Front Psychiatry [Internet]. 2021 [cited 2023 Feb 4];12. Available from: 10.3389/fpsyt.2021.653674<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.653674</pub-id><pub-id pub-id-type="pmcid">PMC8085389</pub-id><pub-id pub-id-type="pmid">33935838</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Samuels EA, Clark SA, Wunsch C, Keeler LAJ, Reddy N, Vanjani R, et al. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 202010.1097/ADM.0000000000000685<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000685</pub-id><pub-id pub-id-type="pmcid">PMC7236851</pub-id><pub-id pub-id-type="pmid">32404652</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Volk J, O&#8217;Brien M, Goe CL. State telemedicine coverage requirements continue to evolve [Internet]. The Commonwealth Fund - Achieving Universal Coverage. 2022 [cited 2023 Feb 9]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.commonwealthfund.org/blog/2022/state-telemedicine-coverage-requirements-continue-evolve">https://www.commonwealthfund.org/blog/2022/state-telemedicine-coverage-requirements-continue-evolve</ext-link></mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kessel</surname><given-names>R</given-names></name><name name-style="western"><surname>Hrzic</surname><given-names>R</given-names></name><name name-style="western"><surname>O&#8217;Nuallain</surname><given-names>E</given-names></name><name name-style="western"><surname>Weir</surname><given-names>E</given-names></name><name name-style="western"><surname>Wong</surname><given-names>BLH</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Digital health paradox: international policy perspectives to address increased health inequalities for people living with disabilities</article-title><source>J Med Internet Res</source><year>2022</year><volume>24</volume><issue>2</issue><fpage>e33819</fpage><pub-id pub-id-type="doi">10.2196/33819</pub-id><pub-id pub-id-type="pmid">35191848</pub-id><pub-id pub-id-type="pmcid">PMC8905475</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kessel</surname><given-names>R</given-names></name><name name-style="western"><surname>Kyriopoulos</surname><given-names>I</given-names></name><name name-style="western"><surname>Wong</surname><given-names>BLH</given-names></name><name name-style="western"><surname>Mossialos</surname><given-names>E</given-names></name></person-group><article-title>The effect of the COVID-19 pandemic on digital health&#8211;seeking behavior: big data interrupted time-series analysis of Google Trends</article-title><source>J Med Internet Res</source><year>2023</year><volume>25</volume><issue>1</issue><fpage>e42401</fpage><pub-id pub-id-type="doi">10.2196/42401</pub-id><pub-id pub-id-type="pmid">36603152</pub-id><pub-id pub-id-type="pmcid">PMC9848442</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Patel NA. Medicare billing codes for digital therapeutics: a path forward. Health Aff Forefr [Internet]. 2022 [cited 2022 Oct 20]; Available from: 10.1377/forefront.20220805.305660/full/</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorn</surname><given-names>SD</given-names></name></person-group><article-title>Backslide or forward progress? Virtual care at U.S. healthcare systems beyond the COVID-19 pandemic</article-title><source>Npj Digit Med.</source><year>2021</year><volume>4</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/s41746-020-00379-z</pub-id><pub-id pub-id-type="pmid">33420420</pub-id><pub-id pub-id-type="pmcid">PMC7794212</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Mark TL, Treiman K, Padwa H, Henretty K, Tzeng J, Gilbert M. Addiction treatment and telehealth: review of efficacy and provider insights during the COVID-19 pandemic. Psychiatr Serv [Internet]. 2021 Oct 13 [cited 2023 Feb 4]; Available from: 10.1176/appi.ps.202100088<pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ps.202100088</pub-id><pub-id pub-id-type="pmid">34644125</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorsey</surname><given-names>ER</given-names></name><name name-style="western"><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>State of Telehealth</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>2</issue><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1601705</pub-id><pub-id pub-id-type="pmid">27410924</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">LaRosa J. Avoiding the cliff: medicare coverage of telemental health and the end of the PHE [Internet]. The Commonwealth Fund - Improving Health Care Quality. 2022 [cited 2023 Feb 9]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.commonwealthfund.org/blog/2022/avoiding-cliff-medicare-coverage-telemental-health-and-end-phe">https://www.commonwealthfund.org/blog/2022/avoiding-cliff-medicare-coverage-telemental-health-and-end-phe</ext-link></mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>WD</given-names></name><name name-style="western"><surname>Bolinski</surname><given-names>R</given-names></name><name name-style="western"><surname>Bresett</surname><given-names>J</given-names></name><name name-style="western"><surname>Ham</surname><given-names>BV</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>S</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><etal/></person-group><article-title>COVID-19 During the opioid epidemic &#8211; exacerbation of stigma and vulnerabilities</article-title><source>J Rural Health</source><year>2021</year><volume>37</volume><issue>1</issue><fpage>172</fpage><pub-id pub-id-type="doi">10.1111/jrh.12442</pub-id><pub-id pub-id-type="pmid">32277731</pub-id><pub-id pub-id-type="pmcid">PMC7262104</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>SK</given-names></name><name name-style="western"><surname>Webster</surname><given-names>RK</given-names></name><name name-style="western"><surname>Smith</surname><given-names>LE</given-names></name><name name-style="western"><surname>Woodland</surname><given-names>L</given-names></name><name name-style="western"><surname>Wessely</surname><given-names>S</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>N</given-names></name><etal/></person-group><article-title>The psychological impact of quarantine and how to reduce it: rapid review of the evidence</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10227</issue><fpage>912</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30460-8</pub-id><pub-id pub-id-type="pmid">32112714</pub-id><pub-id pub-id-type="pmcid">PMC7158942</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czeisler</surname><given-names>M&#201;</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>JF</given-names></name><name name-style="western"><surname>Facer-Childs</surname><given-names>ER</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>R</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>MD</given-names></name><name name-style="western"><surname>Barger</surname><given-names>LK</given-names></name><etal/></person-group><article-title>Mental health, substance use, and suicidal ideation during a prolonged COVID-19-related lockdown in a region with low SARS-CoV-2 prevalence</article-title><source>J Psychiatr Res</source><year>2021</year><volume>140</volume><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2021.05.080</pub-id><pub-id pub-id-type="pmid">34174556</pub-id><pub-id pub-id-type="pmcid">PMC8177437</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oesterle</surname><given-names>TS</given-names></name><name name-style="western"><surname>Kolla</surname><given-names>B</given-names></name><name name-style="western"><surname>Risma</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Breitinger</surname><given-names>SA</given-names></name><name name-style="western"><surname>Rakocevic</surname><given-names>DB</given-names></name><name name-style="western"><surname>Loukianova</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Substance use disorders and telehealth in the COVID-19 pandemic era: a new outlook</article-title><source>Mayo Clin Proc</source><year>2020</year><volume>95</volume><issue>12</issue><fpage>2709</fpage><lpage>2718</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2020.10.011</pub-id><pub-id pub-id-type="pmid">33276843</pub-id><pub-id pub-id-type="pmcid">PMC7577694</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Collision of the COVID-19 and addiction epidemics</article-title><source>Ann Intern Med</source><year>2020</year><volume>173</volume><issue>1</issue><fpage>61</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.7326/M20-1212</pub-id><pub-id pub-id-type="pmid">32240293</pub-id><pub-id pub-id-type="pmcid">PMC7138334</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasylyeva</surname><given-names>TI</given-names></name><name name-style="western"><surname>Smyrnov</surname><given-names>P</given-names></name><name name-style="western"><surname>Strathdee</surname><given-names>S</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>SR</given-names></name></person-group><article-title>Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks</article-title><source>J Int AIDS Soc</source><year>2020</year><volume>23</volume><issue>7</issue><fpage>e25583</fpage><pub-id pub-id-type="doi">10.1002/jia2.25583</pub-id><pub-id pub-id-type="pmid">32697423</pub-id><pub-id pub-id-type="pmcid">PMC7375066</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Conte</surname><given-names>B</given-names></name><name name-style="western"><surname>Hinkes</surname><given-names>S</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>M</given-names></name><name name-style="western"><surname>Na</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Norindr</surname><given-names>A</given-names></name><etal/></person-group><article-title>Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic</article-title><source>Harm Reduct J</source><year>2020</year><volume>17</volume><issue>1</issue><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/s12954-020-00438-4</pub-id><pub-id pub-id-type="pmid">33203460</pub-id><pub-id pub-id-type="pmcid">PMC7671179</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gloff</surname><given-names>NE</given-names></name><name name-style="western"><surname>LeNoue</surname><given-names>SR</given-names></name><name name-style="western"><surname>Novins</surname><given-names>DK</given-names></name><name name-style="western"><surname>Myers</surname><given-names>K</given-names></name></person-group><article-title>Telemental health for children and adolescents</article-title><source>Int Rev Psychiatry Abingdon Engl</source><year>2015</year><volume>27</volume><issue>6</issue><fpage>513</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.3109/09540261.2015.1086322</pub-id><pub-id pub-id-type="pmid">26540584</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reay</surname><given-names>RE</given-names></name><name name-style="western"><surname>Looi</surname><given-names>JC</given-names></name><name name-style="western"><surname>Keightley</surname><given-names>P</given-names></name></person-group><article-title>Telehealth mental health services during COVID-19: summary of evidence and clinical practice</article-title><source>Australas Psychiatry Bull R Aust N Z Coll Psychiatr</source><year>2020</year><volume>28</volume><issue>5</issue><fpage>514</fpage><lpage>516</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1039856220943032</pub-id><pub-id pub-id-type="pmcid">PMC7387833</pub-id><pub-id pub-id-type="pmid">32722963</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osenbach</surname><given-names>JE</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>KM</given-names></name><name name-style="western"><surname>Mishkind</surname><given-names>M</given-names></name><name name-style="western"><surname>Smolenski</surname><given-names>DJ</given-names></name></person-group><article-title>Synchronous telehealth technologies in psychotherapy for depression: a meta-analysis</article-title><source>Depress Anxiety</source><year>2013</year><volume>30</volume><issue>11</issue><fpage>1058</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1002/da.22165</pub-id><pub-id pub-id-type="pmid">23922191</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varker</surname><given-names> T</given-names></name><name name-style="western"><surname>Brand</surname><given-names>RM</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J</given-names></name><name name-style="western"><surname>Terhaag</surname><given-names>S</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of synchronous telepsychology interventions for people with anxiety, depression, posttraumatic stress disorder, and adjustment disorder: A rapid evidence assessment</article-title><source>Psychol Serv</source><year>2019</year><volume>16</volume><issue>4</issue><fpage>621</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1037/ser0000239</pub-id><pub-id pub-id-type="pmid">29809025</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vigerland</surname><given-names>S</given-names></name><name name-style="western"><surname>Lenhard</surname><given-names>F</given-names></name><name name-style="western"><surname>Bonnert</surname><given-names>M</given-names></name><name name-style="western"><surname>Lalouni</surname><given-names>M</given-names></name><name name-style="western"><surname>Hedman</surname><given-names>E</given-names></name><name name-style="western"><surname>Ahlen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Internet-delivered cognitive behavior therapy for children and adolescents: a systematic review and meta-analysis</article-title><source>Clin Psychol Rev</source><year>2016</year><volume>50</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.cpr.2016.09.005</pub-id><pub-id pub-id-type="pmid">27668988</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlbring</surname><given-names>P</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>G</given-names></name><name name-style="western"><surname>Cuijpers</surname><given-names>P</given-names></name><name name-style="western"><surname>Riper</surname><given-names>H</given-names></name><name name-style="western"><surname>Hedman-Lagerl&#246;f</surname><given-names>E</given-names></name></person-group><article-title>Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis</article-title><source>Cogn Behav Ther</source><year>2018</year><volume>47</volume><issue>1</issue><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1080/16506073.2017.1401115</pub-id><pub-id pub-id-type="pmid">29215315</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gliske</surname><given-names>K</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>JW</given-names></name><name name-style="western"><surname>Braughton</surname><given-names>JE</given-names></name><name name-style="western"><surname>Waller</surname><given-names>LA</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>QM</given-names></name></person-group><article-title>Telehealth services for substance use disorders during the COVID-19 pandemic: longitudinal assessment of intensive outpatient programming and data collection practices</article-title><source>JMIR Ment Health.</source><year>2022</year><volume>9</volume><issue>3</issue><fpage>e36263</fpage><pub-id pub-id-type="doi">10.2196/36263</pub-id><pub-id pub-id-type="pmid">35285807</pub-id><pub-id pub-id-type="pmcid">PMC8923149</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Nickasch</surname><given-names>M</given-names></name><name name-style="western"><surname>Lander</surname><given-names>L</given-names></name><name name-style="western"><surname>Wen</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Marshalek</surname><given-names>P</given-names></name><etal/></person-group><article-title>Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis</article-title><source>J Addict Med</source><year>2017</year><volume>11</volume><issue>2</issue><fpage>138</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000287</pub-id><pub-id pub-id-type="pmid">28107210</pub-id><pub-id pub-id-type="pmcid">PMC5354971</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donker</surname><given-names>T</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>K</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>A</given-names></name><name name-style="western"><surname>Mackinnon</surname><given-names>A</given-names></name><name name-style="western"><surname>van Straten</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuijpers</surname><given-names>P</given-names></name><etal/></person-group><article-title>Internet-delivered interpersonal psychotherapy versus internet-delivered cognitive behavioral therapy for adults with depressive symptoms: randomized controlled noninferiority trial</article-title><source>J Med Internet Res.</source><year>2013</year><volume>15</volume><issue>5</issue><fpage>e82</fpage><pub-id pub-id-type="doi">10.2196/jmir.2307</pub-id><pub-id pub-id-type="pmid">23669884</pub-id><pub-id pub-id-type="pmcid">PMC3668608</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanova</surname><given-names>E</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>P</given-names></name><name name-style="western"><surname>Ly</surname><given-names>KH</given-names></name><name name-style="western"><surname>Dahlin</surname><given-names>M</given-names></name><name name-style="western"><surname>Vernmark</surname><given-names>K</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>G</given-names></name><etal/></person-group><article-title>Guided and unguided acceptance and commitment therapy for social anxiety disorder and/or panic disorder provided via the Internet and a smartphone application: a randomized controlled trial</article-title><source>J Anxiety Disord</source><year>2016</year><volume>44</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.janxdis.2016.09.012</pub-id><pub-id pub-id-type="pmid">27721123</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name><name name-style="western"><surname>Raheemullah</surname><given-names>A</given-names></name><name name-style="western"><surname>Fenno</surname><given-names>LE</given-names></name><name name-style="western"><surname>Lembke</surname><given-names>A</given-names></name></person-group><article-title>A telehealth inpatient addiction consult service is both feasible and effective in reducing readmission rates</article-title><source>J Addict Dis</source><year>2022</year><volume>12</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10550887.2022.2090822</pub-id><pub-id pub-id-type="pmid">35819268</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gros</surname><given-names>DF</given-names></name><name name-style="western"><surname>Morland</surname><given-names>LA</given-names></name><name name-style="western"><surname>Greene</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Acierno</surname><given-names>R</given-names></name><name name-style="western"><surname>Strachan</surname><given-names>M</given-names></name><name name-style="western"><surname>Egede</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Delivery of evidence-based psychotherapy via video telehealth</article-title><source>J Psychopathol Behav Assess</source><year>2013</year><volume>35</volume><issue>4</issue><fpage>506</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1007/s10862-013-9363-4</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>VL</given-names></name><name name-style="western"><surname>Stoller</surname><given-names>KB</given-names></name><name name-style="western"><surname>Kidorf</surname><given-names>M</given-names></name><name name-style="western"><surname>Kindbom</surname><given-names>K</given-names></name><name name-style="western"><surname>Hursh</surname><given-names>S</given-names></name><name name-style="western"><surname>Brady</surname><given-names>T</given-names></name><etal/></person-group><article-title>Assessing the effectiveness of an Internet-based videoconferencing platform for delivering intensified substance abuse counseling</article-title><source>J Subst Abuse Treat</source><year>2009</year><volume>36</volume><issue>3</issue><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2008.06.011</pub-id><pub-id pub-id-type="pmid">18775625</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eibl</surname><given-names>JK</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>G</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>D</given-names></name><name name-style="western"><surname>Daiter</surname><given-names>J</given-names></name><name name-style="western"><surname>Varenbut</surname><given-names>M</given-names></name><name name-style="western"><surname>Hogenbirk</surname><given-names>JC</given-names></name><etal/></person-group><article-title>The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting</article-title><source>Drug Alcohol Depend.</source><year>2017</year><volume>176</volume><fpage>133</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.01.048</pub-id><pub-id pub-id-type="pmid">28535455</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visanuyothin</surname><given-names>T</given-names></name><name name-style="western"><surname>SomchaiChakrabhand</surname><given-names>ML</given-names></name><name name-style="western"><surname>Bhugra</surname><given-names>D</given-names></name></person-group><article-title>Tsunami and mental health in Thailand</article-title><source>Int Rev Psychiatry</source><year>2006</year><volume>18</volume><issue>3</issue><fpage>271</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1080/09540260600656217</pub-id><pub-id pub-id-type="pmid">16753665</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubley</surname><given-names>S</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>SB</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>C</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M</given-names></name><name name-style="western"><surname>Shore</surname><given-names>J</given-names></name></person-group><article-title>Review of key telepsychiatry outcomes</article-title><source>World J Psychiatry</source><year>2016</year><volume>6</volume><issue>2</issue><fpage>269</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.5498/wjp.v6.i2.269</pub-id><pub-id pub-id-type="pmid">27354970</pub-id><pub-id pub-id-type="pmcid">PMC4919267</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>ANC</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>AG</given-names></name><name name-style="western"><surname>Stitzer</surname><given-names>M</given-names></name><name name-style="western"><surname>Miele</surname><given-names>GM</given-names></name><name name-style="western"><surname>Polsky</surname><given-names>D</given-names></name><etal/></person-group><article-title>Internet-delivered treatment for substance abuse: a multisite randomized controlled trial</article-title><source>Am J Psychiatry</source><year>2014</year><volume>171</volume><issue>6</issue><fpage>683</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2014.13081055</pub-id><pub-id pub-id-type="pmid">24700332</pub-id><pub-id pub-id-type="pmcid">PMC4079279</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weintraub</surname><given-names>E</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>AD</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J</given-names></name><name name-style="western"><surname>Himelhoch</surname><given-names>S</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>C</given-names></name></person-group><article-title>Expanding access to buprenorphine treatment in rural areas with the use of telemedicine</article-title><source>Am J Addict</source><year>2018</year><volume>27</volume><issue>8</issue><fpage>612</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1111/ajad.12805</pub-id><pub-id pub-id-type="pmid">30265425</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molfenter</surname><given-names>T</given-names></name><name name-style="western"><surname>Roget</surname><given-names>N</given-names></name><name name-style="western"><surname>Chaple</surname><given-names>M</given-names></name><name name-style="western"><surname>Behlman</surname><given-names>S</given-names></name><name name-style="western"><surname>Cody</surname><given-names>O</given-names></name><name name-style="western"><surname>Hartzler</surname><given-names>B</given-names></name><etal/></person-group><article-title>Use of telehealth in substance use disorder services during and after COVID-19: online survey study</article-title><source>JMIR Ment Health</source><year>2021</year><volume>8</volume><issue>2</issue><fpage>e25835</fpage><pub-id pub-id-type="doi">10.2196/25835</pub-id><pub-id pub-id-type="pmid">33481760</pub-id><pub-id pub-id-type="pmcid">PMC7895293</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kessel</surname><given-names>R</given-names></name><name name-style="western"><surname>Wong</surname><given-names>BLH</given-names></name><name name-style="western"><surname>Forman</surname><given-names>R</given-names></name><name name-style="western"><surname>Gabrani</surname><given-names>J</given-names></name><name name-style="western"><surname>Mossialos</surname><given-names>E</given-names></name></person-group><article-title>The European Health Data Space fails to bridge digital divides</article-title><source>BMJ</source><year>2022</year><volume>8</volume><issue>378</issue><fpage>e071913</fpage><pub-id pub-id-type="doi">10.1136/bmj-2022-071913</pub-id><pub-id pub-id-type="pmid">35803600</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drake</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lurie</surname><given-names>N</given-names></name><name name-style="western"><surname>Kraemer</surname><given-names>K</given-names></name><name name-style="western"><surname>Polsky</surname><given-names>D</given-names></name><name name-style="western"><surname>Chaiyachati</surname><given-names>KH</given-names></name></person-group><article-title>Policies to improve substance use disorder treatment with telehealth during the COVID-19 Pandemic and Beyond</article-title><source>J Addict Med</source><year>2020</year><volume>14</volume><issue>5</issue><fpage>e139</fpage><lpage>e141</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000727</pub-id><pub-id pub-id-type="pmid">32826619</pub-id><pub-id pub-id-type="pmcid">PMC8006065</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughto</surname><given-names>JMW</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>L</given-names></name><name name-style="western"><surname>Perry</surname><given-names>NS</given-names></name><name name-style="western"><surname>Donoyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Mimiaga</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>KM</given-names></name><etal/></person-group><article-title>The provision of counseling to patients receiving medications for opioid use disorder: telehealth innovations and challenges in the age of COVID-19</article-title><source>J Subst Abuse Treat</source><year>2021</year><volume>120</volume><fpage>108163</fpage><pub-id pub-id-type="doi">10.1016/j.jsat.2020.108163</pub-id><pub-id pub-id-type="pmid">33298301</pub-id><pub-id pub-id-type="pmcid">PMC7545305</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metzl</surname><given-names>JM</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>DE</given-names></name></person-group><article-title>Structural competency meets structural racism: race, politics, and the structure of medical knowledge</article-title><source>AMA J Ethics</source><year>2014</year><volume>16</volume><issue>9</issue><fpage>674</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1001/virtualmentor.2014.16.9.spec1-1409</pub-id><pub-id pub-id-type="pmid">25216304</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metzl</surname><given-names>JM</given-names></name><name name-style="western"><surname>Maybank</surname><given-names>A</given-names></name><name name-style="western"><surname>De Maio</surname><given-names>F</given-names></name></person-group><article-title>Responding to the COVID-19 pandemic: the need for a structurally competent health care system</article-title><source>JAMA</source><year>2020</year><volume>324</volume><issue>3</issue><fpage>231</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.9289</pub-id><pub-id pub-id-type="pmid">32496531</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehtani</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Ristau</surname><given-names>JT</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>H</given-names></name><name name-style="western"><surname>Surlyn</surname><given-names>C</given-names></name><name name-style="western"><surname>Eveland</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith-Bernardin</surname><given-names>S</given-names></name><etal/></person-group><article-title>COVID-19: a catalyst for change in telehealth service delivery for opioid use disorder management</article-title><source>Subst Abuse</source><year>2021</year><volume>42</volume><issue>2</issue><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1080/08897077.2021.1890676</pub-id><pub-id pub-id-type="pmid">33684331</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiff</surname><given-names>DM</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Hood</surname><given-names>M</given-names></name><name name-style="western"><surname>Bernson</surname><given-names>D</given-names></name><name name-style="western"><surname>Diop</surname><given-names>H</given-names></name><etal/></person-group><article-title>Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts</article-title><source>Obstet Gynecol</source><year>2018</year><volume>132</volume><issue>2</issue><fpage>466</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1097/AOG.0000000000002734</pub-id><pub-id pub-id-type="pmid">29995730</pub-id><pub-id pub-id-type="pmcid">PMC6060005</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guille</surname><given-names>C</given-names></name><name name-style="western"><surname>McCauley</surname><given-names>JL</given-names></name><name name-style="western"><surname>Moreland</surname><given-names>A</given-names></name></person-group><article-title>Leveraging telehealth in the United States to increase access to opioid use disorder treatment in pregnancy and postpartum during the COVID-19 pandemic</article-title><source>Am J Psychiatry</source><year>2021</year><volume>178</volume><issue>4</issue><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2020.20060949</pub-id><pub-id pub-id-type="pmid">33789451</pub-id><pub-id pub-id-type="pmcid">PMC8023749</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lantzsch</surname><given-names>H</given-names></name><name name-style="western"><surname>Panteli</surname><given-names>D</given-names></name><name name-style="western"><surname>Martino</surname><given-names>F</given-names></name><name name-style="western"><surname>Stephani</surname><given-names>V</given-names></name><name name-style="western"><surname>Sei&#223;ler</surname><given-names>D</given-names></name><name name-style="western"><surname>P&#252;schel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Benefit assessment and reimbursement of digital health applications: concepts for setting up a new system for public coverage</article-title><source>Front Publ Health</source><year>2022</year><volume>21</volume><issue>10</issue><fpage>832870</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2022.832870</pub-id><pub-id pub-id-type="pmcid">PMC9068958</pub-id><pub-id pub-id-type="pmid">35530738</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>BLH</given-names></name><name name-style="western"><surname>Maa&#223;</surname><given-names>L</given-names></name><name name-style="western"><surname>Vodden</surname><given-names>A</given-names></name><name name-style="western"><surname>van Kessel</surname><given-names>R</given-names></name><name name-style="western"><surname>Sorbello</surname><given-names>S</given-names></name><name name-style="western"><surname>Buttigieg</surname><given-names>S</given-names></name><etal/></person-group><article-title>The dawn of digital public health in Europe: implications for public health policy and practice</article-title><source>Lancet Reg Health Eur</source><year>2022</year><volume>14</volume><fpage>100316</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2022.100316</pub-id><pub-id pub-id-type="pmid">35132399</pub-id><pub-id pub-id-type="pmcid">PMC8811486</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">van Hattem NE, Silven AV, Bonten TN, Chavannes NH. COVID-19&#8217;s impact on the future of digital health technology in primary care. Fam Pract [Internet]. 2021 Jul 16 [cited 2021 Jul 20];(cmab081)10.1093/fampra/cmab081<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/fampra/cmab081</pub-id><pub-id pub-id-type="pmcid">PMC8344716</pub-id><pub-id pub-id-type="pmid">34268563</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speedie</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>AS</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>J</given-names></name><name name-style="western"><surname>Doarn</surname><given-names>CR</given-names></name></person-group><article-title>Telehealth: the promise of new care delivery models</article-title><source>Telemed E-Health</source><year>2008</year><volume>14</volume><issue>9</issue><fpage>964</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1089/tmj.2008.0114</pub-id><pub-id pub-id-type="pmid">19035808</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Honeyman M, Maguire D, Evans H, Davies A. Digital technology and health inequalities: a scoping review [Internet]. Cardiff: Public Health Wales NHS Trust; 2020 p. 44. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://phw.nhs.wales/publications/publications1/digital-technology-and-health-inequalities-a-scoping-review/">https://phw.nhs.wales/publications/publications1/digital-technology-and-health-inequalities-a-scoping-review/</ext-link></mixed-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Heuvel</surname><given-names>JF</given-names></name><name name-style="western"><surname>Groenhof</surname><given-names>TK</given-names></name><name name-style="western"><surname>Veerbeek</surname><given-names>JH</given-names></name><name name-style="western"><surname>van Solinge</surname><given-names>WW</given-names></name><name name-style="western"><surname>Lely</surname><given-names>AT</given-names></name><name name-style="western"><surname>Franx</surname><given-names>A</given-names></name><etal/></person-group><article-title>eHealth as the next-generation perinatal care: an overview of the literature</article-title><source>J Med Internet Res</source><year>2018</year><volume>20</volume><issue>6</issue><fpage>e9262</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/jmir.9262</pub-id><pub-id pub-id-type="pmcid">PMC6008510</pub-id><pub-id pub-id-type="pmid">29871855</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omboni</surname><given-names>S</given-names></name><name name-style="western"><surname>Padwal</surname><given-names>RS</given-names></name><name name-style="western"><surname>Alessa</surname><given-names>T</given-names></name><name name-style="western"><surname>Bencz&#250;r</surname><given-names>B</given-names></name><name name-style="western"><surname>Green</surname><given-names>BB</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>I</given-names></name><etal/></person-group><article-title>The worldwide impact of telemedicine during COVID-19: current evidence and recommendations for the future</article-title><source>Connect Health</source><year>2022</year><volume>1</volume><fpage>7</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">35233563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20517/ch.2021.03</pub-id><pub-id pub-id-type="pmcid">PMC7612439</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velez</surname><given-names>FF</given-names></name><name name-style="western"><surname>Colman</surname><given-names>S</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruetsch</surname><given-names>C</given-names></name><name name-style="western"><surname>Anastassopoulos</surname><given-names>K</given-names></name></person-group><article-title>Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic</article-title><source>Expert Rev Pharmacoecon Outcomes Res</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1080/14737167.2021.1840357</pub-id><pub-id pub-id-type="pmid">33146558</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitelaw</surname><given-names>S</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>DM</given-names></name><name name-style="western"><surname>Mamas</surname><given-names>MA</given-names></name><name name-style="western"><surname>Cowie</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Spall</surname><given-names>HGC</given-names></name></person-group><article-title>Barriers and facilitators of the uptake of digital health technology in cardiovascular care: a systematic scoping review</article-title><source>Eur Heart J Digit Health</source><year>2021</year><volume>2</volume><issue>1</issue><fpage>62</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1093/ehjdh/ztab005</pub-id><pub-id pub-id-type="pmid">34048508</pub-id><pub-id pub-id-type="pmcid">PMC8139413</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meurk</surname><given-names>C</given-names></name><name name-style="western"><surname>Leung</surname><given-names>J</given-names></name><name name-style="western"><surname>Hall</surname><given-names>W</given-names></name><name name-style="western"><surname>Head</surname><given-names>BW</given-names></name><name name-style="western"><surname>Whiteford</surname><given-names>H</given-names></name></person-group><article-title>Establishing and governing e-mental health care in australia: a systematic review of challenges and a call for policy-focussed research</article-title><source>J Med Internet Res</source><year>2016</year><volume>18</volume><issue>1</issue><fpage>e10</fpage><pub-id pub-id-type="doi">10.2196/jmir.4827</pub-id><pub-id pub-id-type="pmid">26764181</pub-id><pub-id pub-id-type="pmcid">PMC4730106</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harju</surname><given-names>A</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>J</given-names></name></person-group><article-title>The impact of the medicaid expansion on telemental health utilization in four Midwestern states</article-title><source>Telemed E-Health</source><year>2021</year><volume>27</volume><issue>11</issue><fpage>1260</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1089/tmj.2020.0476</pub-id><pub-id pub-id-type="pmid">33428526</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toh</surname><given-names>N</given-names></name><name name-style="western"><surname>Pawlovich</surname><given-names>J</given-names></name><name name-style="western"><surname>Grzybowski</surname><given-names>S</given-names></name></person-group><article-title>Telehealth and patient-doctor relationships in rural and remote communities</article-title><source>Can Fam Physician</source><year>2016</year><volume>62</volume><issue>12</issue><fpage>961</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">27965327</pub-id><pub-id pub-id-type="pmcid">PMC5154642</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monnier</surname><given-names>J</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>RG</given-names></name><name name-style="western"><surname>Frueh</surname><given-names>BC</given-names></name></person-group><article-title>Recent advances in telepsychiatry: an updated review</article-title><source>Psychiatr Serv Wash DC</source><year>2003</year><volume>54</volume><issue>12</issue><fpage>1604</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.54.12.1604</pub-id><pub-id pub-id-type="pmid">14645799</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>YT</given-names></name><name name-style="western"><surname>Weintraub</surname><given-names>E</given-names></name><name name-style="western"><surname>Haffajee</surname><given-names>RL</given-names></name></person-group><article-title>Telemedicine&#8217;s role in addressing the opioid epidemic</article-title><source>Mayo Clin Proc</source><year>2018</year><volume>93</volume><issue>9</issue><fpage>1177</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2018.07.001</pub-id><pub-id pub-id-type="pmid">30097301</pub-id><pub-id pub-id-type="pmcid">PMC6330237</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santesteban-Echarri</surname><given-names>O</given-names></name><name name-style="western"><surname>Piskulic</surname><given-names>D</given-names></name><name name-style="western"><surname>Nyman</surname><given-names>RK</given-names></name><name name-style="western"><surname>Addington</surname><given-names>J</given-names></name></person-group><article-title>Telehealth interventions for schizophrenia-spectrum disorders and clinical high-risk for psychosis individuals: a scoping review</article-title><source>J Telemed Telecare.</source><year>2020</year><volume>26</volume><issue>1&#8211;2</issue><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1177/1357633X18794100</pub-id><pub-id pub-id-type="pmid">30134781</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naslund</surname><given-names>JA</given-names></name><name name-style="western"><surname>Marsch</surname><given-names>LA</given-names></name><name name-style="western"><surname>McHugo</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>SJ</given-names></name></person-group><article-title>Emerging mHealth and eHealth interventions for serious mental illness: a review of the literature</article-title><source>J Ment Health Abingdon Engl</source><year>2015</year><volume>24</volume><issue>5</issue><fpage>321</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.3109/09638237.2015.1019054</pub-id><pub-id pub-id-type="pmcid">PMC4924808</pub-id><pub-id pub-id-type="pmid">26017625</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Kearney</surname><given-names>R</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>RL</given-names></name><name name-style="western"><surname>Calear</surname><given-names>AL</given-names></name></person-group><article-title>Are claims of non-inferiority of Internet and computer-based cognitive-behavioural therapy compared with in-person cognitive-behavioural therapy for adults with anxiety disorders supported by the evidence from head-to-head randomised controlled trials? A systematic review</article-title><source>Aust N Z J Psychiatry</source><year>2019</year><volume>53</volume><issue>9</issue><fpage>851</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1177/0004867419864433</pub-id><pub-id pub-id-type="pmid">31339342</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faragher</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YSD</given-names></name><name name-style="western"><surname>Low</surname><given-names>V</given-names></name><name name-style="western"><surname>Folds</surname><given-names>D</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name></person-group><article-title>Utilization of telehealth technology in addiction treatment in Colorado</article-title><source>J Technol Behav Sci</source><year>2018</year><volume>3</volume><issue>4</issue><fpage>226</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/s41347-018-0057-3</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connolly</surname><given-names>SL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>MS</given-names></name></person-group><article-title>A systematic review of providers&#8217; attitudes toward telemental health via videoconferencing</article-title><source>Clin Psychol Sci Pract.</source><year>2020</year><volume>27</volume><issue>2</issue><fpage>e12311</fpage><pub-id pub-id-type="doi">10.1111/cpsp.12311</pub-id><pub-id pub-id-type="pmcid">PMC9367168</pub-id><pub-id pub-id-type="pmid">35966216</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zentner</surname><given-names>K</given-names></name><name name-style="western"><surname>Gaine</surname><given-names>G</given-names></name><name name-style="western"><surname>Ethridge</surname><given-names>P</given-names></name><name name-style="western"><surname>Surood</surname><given-names>S</given-names></name><name name-style="western"><surname>Abba-Aji</surname><given-names>A</given-names></name></person-group><article-title>Clinicians&#8217; attitudes toward telepsychology in addiction and mental health services, and prediction of postpandemic telepsychology uptake: cross-sectional study</article-title><source>JMIR Form Res</source><year>2022</year><volume>6</volume><issue>5</issue><fpage>e35535</fpage><pub-id pub-id-type="doi">10.2196/35535</pub-id><pub-id pub-id-type="pmid">35559793</pub-id><pub-id pub-id-type="pmcid">PMC9143772</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douglas</surname><given-names>MD</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Heggs</surname><given-names>A</given-names></name><name name-style="western"><surname>Wrenn</surname><given-names>G</given-names></name><name name-style="western"><surname>Mack</surname><given-names>DH</given-names></name><name name-style="western"><surname>Rust</surname><given-names>G</given-names></name></person-group><article-title>Assessing telemedicine utilization by using medicaid claims data</article-title><source>Psychiatr Serv Wash DC</source><year>2017</year><volume>68</volume><issue>2</issue><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.201500518</pub-id><pub-id pub-id-type="pmcid">PMC5444290</pub-id><pub-id pub-id-type="pmid">27691381</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></name><name name-style="western"><surname>Cantor</surname><given-names>J</given-names></name><name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></name><name name-style="western"><surname>Busch</surname><given-names>A</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>M</given-names></name></person-group><article-title>Adoption of telemedicine services by substance abuse treatment facilities in the US</article-title><source>J Subst Abuse Treat.</source><year>2020</year><volume>117</volume><fpage>108060</fpage><pub-id pub-id-type="doi">10.1016/j.jsat.2020.108060</pub-id><pub-id pub-id-type="pmid">32811631</pub-id><pub-id pub-id-type="pmcid">PMC7308749</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>E</given-names></name><name name-style="western"><surname>Turvey</surname><given-names>C</given-names></name><name name-style="western"><surname>Augusterfer</surname><given-names>EF</given-names></name></person-group><article-title>Provider barriers to telemental health: obstacles overcome, obstacles remaining</article-title><source>Telemed E-Health</source><year>2013</year><volume>19</volume><issue>6</issue><fpage>433</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1089/tmj.2013.0068</pub-id><pub-id pub-id-type="pmid">23590176</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></name><name name-style="western"><surname>Raja</surname><given-names>P</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></name><name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></name></person-group><article-title>Health center implementation of telemedicine for opioid use disorders: a qualitative assessment of adopters and nonadopters</article-title><source>J Subst Abuse Treat</source><year>2020</year><volume>115</volume><fpage>108037</fpage><pub-id pub-id-type="doi">10.1016/j.jsat.2020.108037</pub-id><pub-id pub-id-type="pmid">32600625</pub-id><pub-id pub-id-type="pmcid">PMC7327134</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>G</given-names></name><name name-style="western"><surname>Cuijpers</surname><given-names>P</given-names></name><name name-style="western"><surname>Craske</surname><given-names>MG</given-names></name><name name-style="western"><surname>McEvoy</surname><given-names>P</given-names></name><name name-style="western"><surname>Titov</surname><given-names>N</given-names></name></person-group><article-title>Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>10</issue><fpage>e13196</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0013196</pub-id><pub-id pub-id-type="pmid">20967242</pub-id><pub-id pub-id-type="pmcid">PMC2954140</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>VanDeMark</surname><given-names>NR</given-names></name><name name-style="western"><surname>Burrell</surname><given-names>NR</given-names></name><name name-style="western"><surname>Lamendola</surname><given-names>WF</given-names></name><name name-style="western"><surname>Hoich</surname><given-names>CA</given-names></name><name name-style="western"><surname>Berg</surname><given-names>NP</given-names></name><name name-style="western"><surname>Medina</surname><given-names>E</given-names></name></person-group><article-title>An exploratory study of engagement in a technology-supported substance abuse intervention</article-title><source>Subst Abuse Treat Prev Policy</source><year>2010</year><volume>8</volume><issue>5</issue><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/1747-597X-5-10</pub-id><pub-id pub-id-type="pmcid">PMC2898791</pub-id><pub-id pub-id-type="pmid">20529338</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durvasula</surname><given-names>R</given-names></name><name name-style="western"><surname>Miller</surname><given-names>TR</given-names></name></person-group><article-title>Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis</article-title><source>Behav Med</source><year>2014</year><volume>40</volume><issue>2</issue><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1080/08964289.2013.866540</pub-id><pub-id pub-id-type="pmid">24274175</pub-id><pub-id pub-id-type="pmcid">PMC3999248</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perle</surname><given-names>JG</given-names></name><name name-style="western"><surname>Nierenberg</surname><given-names>B</given-names></name></person-group><article-title>How Psychological telehealth can alleviate society&#8217;s mental health burden: a literature review</article-title><source>J Technol Hum Serv</source><year>2013</year><volume>31</volume><issue>1</issue><fpage>22</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1080/15228835.2012.760332</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shelby</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Barber</surname><given-names>D</given-names></name><name name-style="western"><surname>Altice</surname><given-names>F</given-names></name></person-group><article-title>Acceptability of an mHealth app that provides harm reduction services among people who inject drugs: survey study</article-title><source>J Med Internet Res</source><year>2021</year><volume>23</volume><issue>7</issue><fpage>e25428</fpage><pub-id pub-id-type="doi">10.2196/25428</pub-id><pub-id pub-id-type="pmid">34259640</pub-id><pub-id pub-id-type="pmcid">PMC8319773</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delisle-Reda</surname><given-names>S</given-names></name><name name-style="western"><surname>Bruneau</surname><given-names>J</given-names></name><name name-style="western"><surname>Martel-Laferri&#232;re</surname><given-names>V</given-names></name></person-group><article-title>Telehealth for people who inject drugs: an acceptable method of treatment but challenging to access</article-title><source>J Addict Dis</source><year>2022</year><volume>40</volume><issue>4</issue><fpage>514</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1080/10550887.2022.2035166</pub-id><pub-id pub-id-type="pmid">35133229</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priester</surname><given-names>MA</given-names></name><name name-style="western"><surname>Browne</surname><given-names>T</given-names></name><name name-style="western"><surname>Iachini</surname><given-names>A</given-names></name><name name-style="western"><surname>Clone</surname><given-names>S</given-names></name><name name-style="western"><surname>DeHart</surname><given-names>D</given-names></name><name name-style="western"><surname>Seay</surname><given-names>KD</given-names></name></person-group><article-title>Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review</article-title><source>J Subst Abuse Treat</source><year>2016</year><volume>61</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2015.09.006</pub-id><pub-id pub-id-type="pmid">26531892</pub-id><pub-id pub-id-type="pmcid">PMC4695242</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Campopiano</surname><given-names>M</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>G</given-names></name><name name-style="western"><surname>McCance-Katz</surname><given-names>E</given-names></name></person-group><article-title>National and state treatment need and capacity for opioid agonist medication-assisted treatment</article-title><source>Am J Public Health</source><year>2015</year><volume>105</volume><issue>8</issue><fpage>e55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2015.302664</pub-id><pub-id pub-id-type="pmid">26066931</pub-id><pub-id pub-id-type="pmcid">PMC4504312</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kessel</surname><given-names>R</given-names></name><name name-style="western"><surname>Wong</surname><given-names>BLH</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>T</given-names></name><name name-style="western"><surname>Brand</surname><given-names>H</given-names></name></person-group><article-title>Digital health literacy as a super determinant of health: more than simply the sum of its parts</article-title><source>Internet Interv</source><year>2022</year><volume>1</volume><issue>27</issue><fpage>100500</fpage><pub-id pub-id-type="doi">10.1016/j.invent.2022.100500</pub-id><pub-id pub-id-type="pmcid">PMC8861384</pub-id><pub-id pub-id-type="pmid">35242586</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></name><name name-style="western"><surname>Busch</surname><given-names>AB</given-names></name><name name-style="western"><surname>Souza</surname><given-names>J</given-names></name><name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></name><name name-style="western"><surname>Rose</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilcock</surname><given-names>A</given-names></name><etal/></person-group><article-title>How is telemedicine being used in opioid and other substance use disorder treatment?</article-title><source>Health Aff</source><year>2018</year><volume>37</volume><issue>12</issue><fpage>1940</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.2018.05134</pub-id><pub-id pub-id-type="pmcid">PMC6671682</pub-id><pub-id pub-id-type="pmid">30633671</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">Barton C. Telemedicine and Addiction Medicine [Internet]. Rockville, MD: American Society of Addiction Medicine; 2018. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.asam.org/advocacy/news/asam-advocacy-blog/2018/02/05/telemedicine-and-addiction-medicine">https://www.asam.org/advocacy/news/asam-advocacy-blog/2018/02/05/telemedicine-and-addiction-medicine</ext-link></mixed-citation></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="other">US Department of Health and Human Services. Telemedicine and prescribing buprenorphine for the treatment of opioid use disorder. 2018.</mixed-citation></ref><ref id="CR89"><label>89.</label><mixed-citation publication-type="other">Kwong MW. Current telehealth policy roundup: CMS and the States [Internet]. Arizona Telemedicine Policy Symposium; 2019 Sep 23 [cited 2023 Feb 7]; Arizona. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://telemedicine.arizona.edu/sites/default/files/2%20Mei%20Kwong.pdf">https://telemedicine.arizona.edu/sites/default/files/2%20Mei%20Kwong.pdf</ext-link></mixed-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="other">115th Congress. S.2680 - Opioid Crisis Response Act of 2018 [Internet]. 2018. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.congress.gov/bill/115th-congress/senate-bill/2680/text">https://www.congress.gov/bill/115th-congress/senate-bill/2680/text</ext-link></mixed-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Verma S. Early impact of CMS expansion of medicare telehealth during COVID-19. Health Aff Forefr [Internet]. 2020 [cited 2022 Oct 21]; Available from: 10.1377/forefront.20200715.454789/full/</mixed-citation></ref><ref id="CR92"><label>92.</label><mixed-citation publication-type="other">Singer JA. MAT Regulations Relaxed During COVID-19 Pandemic&#8212;this should catalyze further reform [Internet]. Cato at Liberty. 2020 [cited 2023 Feb 7]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cato.org/blog/mat-regulations-relaxed-during-covid-19-pandemic-should-catalyze-further-reform">https://www.cato.org/blog/mat-regulations-relaxed-during-covid-19-pandemic-should-catalyze-further-reform</ext-link></mixed-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>TC</given-names></name><name name-style="western"><surname>Bratberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Finnell</surname><given-names>DS</given-names></name></person-group><article-title>Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment</article-title><source>Subst Abuse</source><year>2020</year><volume>41</volume><issue>2</issue><fpage>147</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1080/08897077.2020.1752351</pub-id><pub-id pub-id-type="pmid">32314951</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><mixed-citation publication-type="other">US Department of Health and Human Services. Determination that a public health emergency exists [Internet]. 2020 [cited 2023 Feb 7]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx">https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx</ext-link></mixed-citation></ref><ref id="CR95"><label>95.</label><mixed-citation publication-type="other">US Department of Health and Human Services. Notification of enforcement discretion for telehealth remote communications during the COVID-19 nationwide public health emergency [Internet]. 2020 [cited 2023 Feb 7]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/index.html">https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/index.html</ext-link></mixed-citation></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="other">Substance Abuse and Mental Health Services Administration. Methadone take-home flexibilities extension guidance | SAMHSA [Internet]. 2020 [cited 2023 Feb 7]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines/methadone-guidance">https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines/methadone-guidance</ext-link></mixed-citation></ref><ref id="CR97"><label>97.</label><mixed-citation publication-type="other">Drug Enforcement Agency. DEA/SAMHSA buprenorphine telemedicine [Internet]. 2020 Mar. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf">https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf</ext-link></mixed-citation></ref><ref id="CR98"><label>98.</label><mixed-citation publication-type="other">117th Congress. H.R.4040 - Advancing Telehealth Beyond COVID&#8211;19 Act of 2022 [Internet]. 2022 [cited 2023 Feb 7]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.congress.gov/bill/117th-congress/house-bill/4040">https://www.congress.gov/bill/117th-congress/house-bill/4040</ext-link></mixed-citation></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">117th Congress. H.R.2617 - Consolidated Appropriations Act, 2023 [Internet]. 2022 [cited 2023 Feb 7]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.congress.gov/bill/117th-congress/house-bill/2617">https://www.congress.gov/bill/117th-congress/house-bill/2617</ext-link></mixed-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Compton</surname><given-names>WM</given-names></name><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>G</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs</article-title><source>JAMA Psychiat</source><year>2022</year><volume>79</volume><issue>9</issue><fpage>932</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.1776</pub-id><pub-id pub-id-type="pmcid">PMC9280608</pub-id><pub-id pub-id-type="pmid">35830198</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><mixed-citation publication-type="other">O&#8217;Donnell J. Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls &#8212; United States, 2019&#8211;2020. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2023 Feb 7];70. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7050e3.htm">https://www.cdc.gov/mmwr/volumes/70/wr/mm7050e3.htm</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7050e3</pub-id><pub-id pub-id-type="pmcid">PMC8675656</pub-id><pub-id pub-id-type="pmid">34914673</pub-id></mixed-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Davis</surname><given-names>NL</given-names></name><name name-style="western"><surname>Compton</surname><given-names>WM</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>GT</given-names></name><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><etal/></person-group><article-title>Trends and characteristics of buprenorphine-involved overdose deaths prior to and during the COVID-19 Pandemic</article-title><source>JAMA Netw Open</source><year>2023</year><volume>6</volume><issue>1</issue><fpage>e2251856</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.51856</pub-id><pub-id pub-id-type="pmid">36662523</pub-id><pub-id pub-id-type="pmcid">PMC9860517</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilty</surname><given-names>DM</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>DC</given-names></name><name name-style="western"><surname>Parish</surname><given-names>MB</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>B</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Yellowlees</surname><given-names>PM</given-names></name></person-group><article-title>The effectiveness of telemental health: a 2013 review</article-title><source>Telemed J E-Health Off J Am Telemed Assoc</source><year>2013</year><volume>19</volume><issue>6</issue><fpage>444</fpage><lpage>454</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/tmj.2013.0075</pub-id><pub-id pub-id-type="pmcid">PMC3662387</pub-id><pub-id pub-id-type="pmid">23697504</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>LA</given-names></name><name name-style="western"><surname>Casteel</surname><given-names>D</given-names></name><name name-style="western"><surname>Shigekawa</surname><given-names>E</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>MS</given-names></name><name name-style="western"><surname>Roby</surname><given-names>DH</given-names></name><name name-style="western"><surname>McMenamin</surname><given-names>SB</given-names></name></person-group><article-title>Telemedicine-delivered treatment interventions for substance use disorders: a systematic review</article-title><source>J Subst Abuse Treat</source><year>2019</year><volume>101</volume><fpage>38</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2019.03.007</pub-id><pub-id pub-id-type="pmid">31006553</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilardaga</surname><given-names>R</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>T</given-names></name><name name-style="western"><surname>Palenski</surname><given-names>PE</given-names></name><name name-style="western"><surname>Kumaresan</surname><given-names>V</given-names></name><name name-style="western"><surname>Mannelli</surname><given-names>P</given-names></name><name name-style="western"><surname>Sweitzer</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Review of popularity and quality standards of opioid-related smartphone apps</article-title><source>Curr Addict Rep</source><year>2020</year><volume>7</volume><issue>4</issue><fpage>486</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1007/s40429-020-00344-6</pub-id><pub-id pub-id-type="pmid">33777644</pub-id><pub-id pub-id-type="pmcid">PMC7993400</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelemen</surname><given-names>A</given-names></name><name name-style="western"><surname>Minarcik</surname><given-names>E</given-names></name><name name-style="western"><surname>Steets</surname><given-names>C</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name></person-group><article-title>Telehealth interventions for alcohol use disorder: a systematic review</article-title><source>Liver Res</source><year>2022</year><volume>6</volume><issue>3</issue><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.livres.2022.08.004</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kramer Schmidt</surname><given-names>L</given-names></name><name name-style="western"><surname>Bojesen</surname><given-names>AB</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>AS</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>K</given-names></name></person-group><article-title>Duration of therapy &#8211; does it matter?: a systematic review and meta-regression of the duration of psychosocial treatments for alcohol use disorder</article-title><source>J Subst Abuse Treat</source><year>2018</year><volume>1</volume><issue>84</issue><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2017.11.002</pub-id><pub-id pub-id-type="pmid">29195594</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruse</surname><given-names>CS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Watson</surname><given-names>JB</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>LG</given-names></name><name name-style="western"><surname>Stoppelmoor</surname><given-names>AG</given-names></name><name name-style="western"><surname>Oyibo</surname><given-names>SE</given-names></name></person-group><article-title>Measures of Effectiveness, efficiency, and quality of telemedicine in the management of alcohol abuse, addiction, and rehabilitation: systematic review</article-title><source>J Med Internet Res</source><year>2020</year><volume>22</volume><issue>1</issue><fpage>e13252</fpage><pub-id pub-id-type="doi">10.2196/13252</pub-id><pub-id pub-id-type="pmid">32012048</pub-id><pub-id pub-id-type="pmcid">PMC7055825</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frueh</surname><given-names>BC</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>S</given-names></name><name name-style="western"><surname>Myrick</surname><given-names>H</given-names></name></person-group><article-title>Telehealth service delivery for persons with alcoholism</article-title><source>J Telemed Telecare</source><year>2005</year><volume>11</volume><issue>7</issue><fpage>372</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1177/1357633X0501100701</pub-id><pub-id pub-id-type="pmid">16238840</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlson</surname><given-names>LE</given-names></name><name name-style="western"><surname>Lounsberry</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Maciejewski</surname><given-names>O</given-names></name><name name-style="western"><surname>Wright</surname><given-names>K</given-names></name><name name-style="western"><surname>Collacutt</surname><given-names>V</given-names></name><name name-style="western"><surname>Taenzer</surname><given-names>P</given-names></name></person-group><article-title>Telehealth-delivered group smoking cessation for rural and urban participants: feasibility and cessation rates</article-title><source>Addict Behav</source><year>2012</year><volume>37</volume><issue>1</issue><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2011.09.011</pub-id><pub-id pub-id-type="pmid">21968227</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stead</surname><given-names>LF</given-names></name><name name-style="western"><surname>Hartmann-Boyce</surname><given-names>J</given-names></name><name name-style="western"><surname>Perera</surname><given-names>R</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>T</given-names></name></person-group><article-title>Telephone counselling for smoking cessation</article-title><source>Cochrane Database Syst Rev.</source><year>2013</year><volume>8</volume><fpage>CD002850</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD002850.pub3</pub-id><pub-id pub-id-type="pmid">23934971</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myung</surname><given-names>SK</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>DD</given-names></name><name name-style="western"><surname>Kazinets</surname><given-names>G</given-names></name><name name-style="western"><surname>Seo</surname><given-names>HG</given-names></name><name name-style="western"><surname>Moskowitz</surname><given-names>JM</given-names></name></person-group><article-title>Effects of Web- and computer-based smoking cessation programs: meta-analysis of randomized controlled trials</article-title><source>Arch Intern Med</source><year>2009</year><volume>169</volume><issue>10</issue><fpage>929</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2009.109</pub-id><pub-id pub-id-type="pmid">19468084</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrison</surname><given-names>KA</given-names></name><name name-style="western"><surname>Pal</surname><given-names>P</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>SS</given-names></name><name name-style="western"><surname>Pittman</surname><given-names>BP</given-names></name><name name-style="western"><surname>Gueorguieva</surname><given-names>R</given-names></name><name name-style="western"><surname>Rojiani</surname><given-names>R</given-names></name><etal/></person-group><article-title>Craving to quit: a randomized controlled trial of smartphone app-based mindfulness training for smoking cessation</article-title><source>Nicotine Tob Res Off J Soc Res Nicotine Tob</source><year>2020</year><volume>22</volume><issue>3</issue><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1093/ntr/nty126</pub-id><pub-id pub-id-type="pmcid">PMC7297096</pub-id><pub-id pub-id-type="pmid">29917096</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melamed</surname><given-names>OC</given-names></name><name name-style="western"><surname>Hauck</surname><given-names>TS</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>L</given-names></name><name name-style="western"><surname>Selby</surname><given-names>P</given-names></name><name name-style="western"><surname>Mulsant</surname><given-names>BH</given-names></name></person-group><article-title>COVID-19 and persons with substance use disorders: inequities and mitigation strategies</article-title><source>Subst Abuse</source><year>2020</year><volume>41</volume><issue>3</issue><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1080/08897077.2020.1784363</pub-id><pub-id pub-id-type="pmid">32697172</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edinoff</surname><given-names>AN</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Chauncy</surname><given-names>TM</given-names></name><name name-style="western"><surname>Erwin</surname><given-names>AP</given-names></name><name name-style="western"><surname>Russo</surname><given-names>KM</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Addiction and COVID: issues, challenges, and new telehealth approaches</article-title><source>Psychiatry Int</source><year>2022</year><volume>3</volume><issue>2</issue><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.3390/psychiatryint3020014</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garland</surname><given-names>EL</given-names></name><name name-style="western"><surname>Howard</surname><given-names>MO</given-names></name></person-group><article-title>Mindfulness-based treatment of addiction: current state of the field and envisioning the next wave of research</article-title><source>Addict Sci Clin Pract</source><year>2018</year><volume>13</volume><issue>1</issue><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s13722-018-0115-3</pub-id><pub-id pub-id-type="pmid">29669599</pub-id><pub-id pub-id-type="pmcid">PMC5907295</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><mixed-citation publication-type="other">The Associated Press. Free internet for 48 million U.S. households under plan announced by White House [Internet]. Times-Standard. 2022 [cited 2022 May 13]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.redbluffdailynews.com/2022/05/09/free-internet-for-48-million-u-s-households-under-plan-announced-by-white-house">https://www.redbluffdailynews.com/2022/05/09/free-internet-for-48-million-u-s-households-under-plan-announced-by-white-house</ext-link></mixed-citation></ref></ref-list></ref-list></back></article></pmc-articleset>